The tumor microenvironment: An irreplaceable element of tumor budding and epithelial-mesenchymal transition-mediated cancer metastasis

Cell Adhesion and Migration

Volumn 10, Issue 4, 2016, Pages 434-446

  Li, Hui ^a,b   Xu, Fangying ^a,b   Li, Si ^a,b   Zhong, Anjing ^a,b   Meng, Xianwen ^c   Lai, Maode ^a,b  

^a ZHEJIANG UNIVERSITY SCHOOL OF MEDICINE   (China)

^b Key Laboratory of Neuroscience   (China)

^c ZHEJIANG UNIVERSITY   (China)

Author keywords

cancer metastasis; drug resistance; epithelial mesenchymal transition; microenvironment; tumor budding

Indexed keywords

COLONY STIMULATING FACTOR 1; EPIDERMAL GROWTH FACTOR RECEPTOR; ERLOTINIB; FATTY ACID SYNTHASE; FIBRONECTIN; GLYCOSPHINGOLIPID; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; INTERLEUKIN 1BETA; INTERLEUKIN 6; JANUS KINASE; NERVE CELL ADHESION MOLECULE; PROTEIN BCL 2; STAT3 PROTEIN; TRANSCRIPTION FACTOR SNAIL; TRANSFORMING GROWTH FACTOR BETA; TUMOR NECROSIS FACTOR ALPHA; UVOMORULIN; VASCULOTROPIN; VIMENTIN;

CANCER PROGNOSIS; CARCINOGENESIS; CELL MOTILITY; EPIGENETICS; EPITHELIAL MESENCHYMAL TRANSITION; EXTRACELLULAR MATRIX; GENE MUTATION; HUMAN; HYPOXIA; INFLAMMATION; METASTASIS; MOUTH SQUAMOUS CELL CARCINOMA; MULTIDRUG RESISTANCE; NONHUMAN; REVIEW; TUMOR ASSOCIATED LEUKOCYTE; TUMOR BUDDING; TUMOR GROWTH; TUMOR MICROENVIRONMENT; ANIMAL; METABOLISM; NEOPLASM; PATHOLOGY;

ANIMALS; EPITHELIAL-MESENCHYMAL TRANSITION; EXTRACELLULAR MATRIX; HUMANS; INFLAMMATION; NEOPLASM METASTASIS; NEOPLASMS; TUMOR MICROENVIRONMENT;

EID: 84961206867     PISSN: 19336918     EISSN: 19336926     Source Type: Journal    
DOI: 10.1080/19336918.2015.1129481     Document Type: Review

References (121)

1. F.Prall. Tumour budding in colorectal carcinoma. Histopathol 2007; 50:151-62; http://dx.doi.org/10.1111/j.1365-2559.2006.02551.x
2. B.Mitrovic, D.F.Schaeffer, R.H.Riddell, R.Kirsch. Tumor budding in colorectal carcinoma:time to take notice. Modern Pathol Inc 2012; 25:1315-25; http://dx.doi.org/10.1038/modpathol.2012.94
3. I.Zlobec, A.Lugli. Epithelial mesenchymal transition and tumor budding in aggressive colorectal cancer:tumor budding as oncotarget. Oncotarget 2010; 1:651-61; PMID:21317460; http://dx.doi.org/10.18632/oncotarget.199
4. T.Brabletz, A.Jung, S.Reu, M.Porzner, F.Hlubek, L.A.Kunz-Schughart, R.Knuechel, T.Kirchner. Variable β-catenin expression in colorectal cancers indicates tumor progression driven by the tumor environment. Proc Natl Acad Sci U S A 2001; 98:10356-61
5. T.Imai The growth of human carcinoma:A morphological analysis. Fukuoka Igaku Zasshi 1954; 45:72-102
6. T.Morodomi, H.Isomoto, K.Shirouzu, K.Kakegawa, K.Irie, M.Morimatsu. An index for estimating the probability of lymph node metastasis in rectal cancers. Lymph node metastasis and the histopathology of actively invasive regions of cancer. Cancer 1989; 63:539-43; PMID:2912530; http://dx.doi.org/10.1002/1097-0142(19890201)63:3<539::AID-CNCR2820630323>3.0.CO;2-S
7. K.Hase, C.Shatney, D.Johnson, M.Trollope, M.Vierra. Prognostic value of tumor “budding” in patients with colorectal cancer. Dis Colon Rectum 1993; 36:627-35; PMID:8348847; http://dx.doi.org/10.1007/BF02238588
8. M.Ono, M.Sakamoto, Y.Ino, Y.Moriya, K.Sugihara, T.Muto, S.Hirohashi. Cancer cell morphology at the invasive front and expression of cell adhesion-related carbohydrate in the primary lesion of patients with colorectal carcinoma with liver metastasis. Cancer 1996; 78:1179-86; PMID:8826938; http://dx.doi.org/10.1002/(SICI)1097-0142(19960915)78:6<1179::AID-CNCR3>3.0.CO;2-5
9. N.S.Goldstein, J.Hart. Histologic features associated with lymph node metastasis in stage T1 and superficial T2 rectal adenocarcinomas in abdominoperineal resection specimens. Identifying a subset of patients for whom treatment with adjuvant therapy or completion abdominoperineal resection should be considered after local excision. Am J Clin Pathol 1999; 111:51-8; PMID:9894454
10. T.Okuyama, M.Oya, H.Ishikawa. Budding as a risk factor for lymph node metastasis in pT1 or pT2 well-differentiated colorectal adenocarcinoma. Dis Colon Rectum 2002; 45:628-34; PMID:12004212; http://dx.doi.org/10.1007/s10350-004-6259-0
11. F.Y.Xu, J.K.Dong, Y.M.Zhu, M.J.Qu, F.J.Wang, Y.S.Jin, G.P.Ren, M.D.Lai. Study on independent factors on the prognosis of colorectal carcinoma:TNM stage, tumor budding, perineural invasion, peritumoral-lymphocytic infiltration and urine glucose. Zhonghua liu xing bing xue za zhi 2005; 26:366-9; PMID:16053766
12. M.Katoh. Network of WNT and other regulatory signaling cascades in pluripotent stem cells and cancer stem cells. Curr Pharmaceutical Biotechnol 2011; 12:160-70; http://dx.doi.org/10.2174/138920111794295710
13. H.Acloque, M.S.Adams, K.Fishwick, M.Bronner-Fraser, M.A.Nieto. Epithelial-mesenchymal transitions:the importance of changing cell state in development and disease. J Clin Invest 2009; 119:1438-49; PMID:19487820; http://dx.doi.org/10.1172/JCI38019
14. J.P.Thiery, H.Acloque, R.Y.Huang, M.A.Nieto. Epithelial-mesenchymal transitions in development and disease. Cell 2009; 139:871-90; PMID:19945376; http://dx.doi.org/10.1016/j.cell.2009.11.007
15. J.H.Tsai, J.L.Donaher, D.A.Murphy, S.Chau, J.Yang. Spatiotemporal regulation of epithelial-mesenchymal transition is essential for squamous cell carcinoma metastasis. Cancer Cell 2012; 22:725-36; PMID:23201165; http://dx.doi.org/10.1016/j.ccr.2012.09.022
16. S.B.Krantz, M.A.Shields, S.Dangi-Garimella, H.G.Munshi, D.J.Bentrem. Contribution of epithelial-to-mesenchymal transition and cancer stem cells to pancreatic cancer progression. J Surg Res 2012; 173:105-12; PMID:22099597; http://dx.doi.org/10.1016/j.jss.2011.09.020
17. Y.Kang, J.Massague. Epithelial-mesenchymal transitions:twist in development and metastasis. Cell 2004; 118:277-9; PMID:15294153; http://dx.doi.org/10.1016/j.cell.2004.07.011
18. N.Tiwari, V.K.Tiwari, L.Waldmeier, P.J.Balwierz, P.Arnold, M.Pachkov, N.Meyer-Schaller, D.Schübeler, E.van Nimwegen, G.Christofori. Sox4 is a master regulator of epithelial-mesenchymal transition by controlling Ezh2 expression and epigenetic reprogramming. Cancer Cell 2013; 23:768-83; PMID:23764001; http://dx.doi.org/10.1016/j.ccr.2013.04.020
19. Y.Jing, Z.Han, S.Zhang, Y.Liu, L.Wei. Epithelial-Mesenchymal Transition in tumor microenvironment. Cell Biosci 2011; 1:29; PMID:21880137; http://dx.doi.org/10.1186/2045-3701-1-29
20. N.E.Sounni, A.Noel. Targeting the tumor microenvironment for cancer therapy. Clin Chem 2013; 59:85-93; PMID:23193058; http://dx.doi.org/10.1373/clinchem.2012.185363
21. D.M.Gonzalez, D.Medici. Signaling mechanisms of the epithelial-mesenchymal transition. Sci Signal 2014; 7:re8; PMID:25249658; http://dx.doi.org/10.1126/scisignal.2005189
22. H.Peinado, D.Olmeda, A.Cano. Snail, Zeb and bHLH factors in tumour progression:an alliance against the epithelial phenotype?. Nature Rev Cancer 2007; 7:415-28; http://dx.doi.org/10.1038/nrc2131
23. E.Casas, J.Kim, A.Bendesky, L.Ohno-Machado, C.J.Wolfe, J.Yang. Snail2 is an essential mediator of Twist1-induced epithelial mesenchymal transition and metastasis. Cancer Res 2011; 71:245-54; PMID:21199805; http://dx.doi.org/10.1158/0008-5472.CAN-10-2330
24. M.A.Nieto The ins and outs of the epithelial to mesenchymal transition in health and disease. Ann Rev Cell Dev Biol 2011; 27:347-76; http://dx.doi.org/10.1146/annurev-cellbio-092910-154036
25. J.C.Tse, R.Kalluri. Mechanisms of metastasis:epithelial-to-mesenchymal transition and contribution of tumor microenvironment. J Cell Biochem 2007; 101:816-29; PMID:17243120; http://dx.doi.org/10.1002/jcb.21215
26. S.Kazama, T.Watanabe, Y.Ajioka, T.Kanazawa, H.Nagawa. Tumour budding at the deepest invasive margin correlates with lymph node metastasis in submucosal colorectal cancer detected by anticytokeratin antibody CAM5.2. Br J Cancer 2006; 94:293-8; PMID:16404429; http://dx.doi.org/10.1038/sj.bjc.6602927
27. S.S.Yusra, Semba S, H.Yokozaki. Biological significance of tumor budding at the invasive front of human colorectal carcinoma cells. Int J Oncol 2012; 41:201-10; PMID:22569829
28. S.Paget. The distribution of secondary growths in cancer of the breast. 1889. Cancer Metastasis Rev 1989; 8:98-101; PMID:2673568
29. L.A.Liotta, E.C.Kohn. The microenvironment of the tumour-host interface. Nature 2001; 411:375-9; PMID:11357145; http://dx.doi.org/10.1038/35077241
30. G.Landskron, M.De la Fuente, P.Thuwajit, C.Thuwajit, M.A.Hermoso. Chronic inflammation and cytokines in the tumor microenvironment. J Immunol Res 2014; 2014:149185; PMID:24901008; http://dx.doi.org/10.1155/2014/149185
31. F.Gao, B.Liang, S.T.Reddy, R.Farias-Eisner, X.Su. Role of inflammation-associated microenvironment in tumorigenesis and metastasis. Curr Cancer Drug Targets 2014; 14:30-45; PMID:24200082; http://dx.doi.org/10.2174/15680096113136660107
32. T.Leibovich-Rivkin, Y.Liubomirski, B.Bernstein, T.Meshel, A.Ben-Baruch. Inflammatory factors of the tumor microenvironment induce plasticity in nontransformed breast epithelial cells:EMT, invasion, and collapse of normally organized breast textures. Neoplasia 2013; 15:1330-46; PMID:24403855; http://dx.doi.org/10.1593/neo.131688
33. G.Soria, M.Ofri-Shahak, I.Haas, N.Yaal-Hahoshen, L.Leider-Trejo, T.Leibovich-Rivkin, P.Weitzenfeld, T.Meshel, E.Shabtai, M.Gutman, et al. Inflammatory mediators in breast cancer:coordinated expression of TNFalpha & IL-1beta with CCL2 & CCL5 and effects on epithelial-to-mesenchymal transition. BMC Cancer 2011; 11:130; PMID:21486440; http://dx.doi.org/10.1186/1471-2407-11-130
34. H.L.Chua, P.Bhat-Nakshatri, S.E.Clare, A.Morimiya, S.Badve, H.Nakshatri. NF-kappaB represses E-cadherin expression and enhances epithelial to mesenchymal transition of mammary epithelial cells:potential involvement of ZEB-1 and ZEB-2. Oncogene 2007; 26:711-24; PMID:16862183; http://dx.doi.org/10.1038/sj.onc.1209808
35. B.B.Aggarwal Signalling pathways of the TNF superfamily:a double-edged sword. Nat Rev Immunol 2003; 3:745-56; PMID:12949498; http://dx.doi.org/10.1038/nri1184
36. M.Karin, F.R.Greten. NF-kappaB:linking inflammation and immunity to cancer development and progression. Nat Rev Immunol 2005; 5:749-59; PMID:16175180; http://dx.doi.org/10.1038/nri1703
37. A.R.Bresnick, D.J.Weber, D.B.Zimmer. S100 proteins in cancer. Nat Rev Cancer 2015; 15:96-109; PMID:25614008; http://dx.doi.org/10.1038/nrc3893
38. R.Singh, B.S.Shankar, K.B.Sainis. TGF-beta1-ROS-ATM-CREB signaling axis in macrophage mediated migration of human breast cancer MCF7 cells. Cell Signal 2014; 26:1604-15; PMID:24705025; http://dx.doi.org/10.1016/j.cellsig.2014.03.028
39. B.R.Achyut, L.Yang. Transforming growth factor-β in the gastrointestinal and hepatic tumor microenvironment. Gastroenterology 2011; 141:1167-78; PMID:21839702; http://dx.doi.org/10.1053/j.gastro.2011.07.048
40. J.Fuxe, T.Vincent, A.Garcia de Herreros. Transcriptional crosstalk between TGF-β and stem cell pathways in tumor cell invasion:role of EMT promoting Smad complexes. Cell cycle 2010; 9:2363-74; PMID:20519943; http://dx.doi.org/10.4161/cc.9.12.12050
41. J.A.Shin, O.K.Hong, H.J.Lee, S.Y.Jeon, J.W.Kim, S.H.Lee, J.H.Cho, J.M.Lee, Y.H.Choi, S.A.Chang, et al. Transforming growth factor-β induces epithelial to mesenchymal transition and suppresses the proliferation and transdifferentiation of cultured human pancreatic duct cells. J Cell Biochem 2011; 112:179-88; PMID:21069735; http://dx.doi.org/10.1002/jcb.22929
42. L.Zhu, H.Qin, P.Y.Li, S.N.Xu, H.F.Pang, H.Z.Zhao, D.M.Li, Q.Zhao. Response gene to complement-32 enhances metastatic phenotype by mediating transforming growth factor β-induced epithelial-mesenchymal transition in human pancreatic cancer cell line BxPC-3. J Exp Clin Cancer Res 2012; 31:29; PMID:22458379; http://dx.doi.org/10.1186/1756-9966-31-29
43. C.Birchmeier, W.Birchmeier, E.Gherardi, G.F.Vande Woude. Met, metastasis, motility and more. Nat Rev Mol Cell Biol 2003; 4:915-25; PMID:14685170; http://dx.doi.org/10.1038/nrm1261
44. L.Trusolino, A.Bertotti, P.M.Comoglio. MET signalling:principles and functions in development, organ regeneration and cancer. Nat Rev Mol Cell Biol 2010; 11:834-48; PMID:21102609; http://dx.doi.org/10.1038/nrm3012
45. A.Abulaiti, Y.Shintani, S.Funaki, T.Nakagiri, M.Inoue, N.Sawabata, M.Minami, M.Okumura. Interaction between non-small-cell lung cancer cells and fibroblasts via enhancement of TGF-β signaling by IL-6. Lung Cancer 2013; 82:204-13; PMID:24011634; http://dx.doi.org/10.1016/j.lungcan.2013.08.008
46. A.Yadav, B.Kumar, J.Datta, T.N.Teknos, P.Kumar. IL-6 promotes head and neck tumor metastasis by inducing epithelial-mesenchymal transition via the JAK-STAT3-SNAIL signaling pathway. Mol Cancer Res 2011; 9:1658-67; PMID:21976712; http://dx.doi.org/10.1158/1541-7786.MCR-11-0271
47. R.N.Kaplan, R.D.Riba, S.Zacharoulis, A.H.Bramley, L.Vincent, C.Costa, D.D.MacDonald, D.K.Jin, K.Shido, S.A.Kerns, et al. VEGFR1-positive haematopoietic bone marrow progenitors initiate the pre-metastatic niche. Nature 2005; 438:820-7; PMID:16341007; http://dx.doi.org/10.1038/nature04186
48. B.Psaila, D.Lyden. The metastatic niche:adapting the foreign soil. Nature Rev Cancer 2009; 9:285-93; http://dx.doi.org/10.1038/nrc2621
49. J.Sceneay, M.J.Smyth, A.Moller. The pre-metastatic niche:finding common ground. Cancer Metastasis Rev 2013; 32:449-64; PMID:23636348; http://dx.doi.org/10.1007/s10555-013-9420-1
50. J.E.Ohm, D.P.Carbone. VEGF as a mediator of tumor-associated immunodeficiency. Immunologic Res 2001; 23:263-72; http://dx.doi.org/10.1385/IR:23:2-3:263
51. H.W.Wang, J.A.Joyce. Alternative activation of tumor-associated macrophages by IL-4:priming for protumoral functions. Cell Cycle 2010; 9:4824-35; PMID:21150330; http://dx.doi.org/10.4161/cc.9.24.14322
52. Q.W.Zhang, L.Liu, C.Y.Gong, H.S.Shi, Y.H.Zeng, X.Z.Wang, Y.W.Zhao, Y.Q.Wei. Prognostic significance of tumor-associated macrophages in solid tumor:a meta-analysis of the literature. PloS One 2012; 7:e50946; PMID:23284651; http://dx.doi.org/10.1371/journal.pone.0050946
53. B.Z.Qian, J.W.Pollard. Macrophage diversity enhances tumor progression and metastasis. Cell 2010; 141:39-51; PMID:20371344; http://dx.doi.org/10.1016/j.cell.2010.03.014
54. S.Su, Q.Liu, J.Chen, J.Chen, F.Chen, C.He, D.Huang, W.Wu, L.Lin, W.Huang, et al. A positive feedback loop between mesenchymal-like cancer cells and macrophages is essential to breast cancer metastasis. Cancer Cell 2014; 25:605-20; PMID:24823638; http://dx.doi.org/10.1016/j.ccr.2014.03.021
55. C.Y.Liu, J.Y.Xu, X.Y.Shi, W.Huang, T.Y.Ruan, P.Xie, J.L.Ding. M2-polarized tumor-associated macrophages promoted epithelial-mesenchymal transition in pancreatic cancer cells, partially through TLR4/IL-10 signaling pathway. Lab Investi J Tech Methods Pathol 2013; 93:844-54; http://dx.doi.org/10.1038/labinvest.2013.69
56. J.Ou, Y.Peng, J.Deng, H.Miao, J.Zhou, L.Zha, R.Zhou, L.Yu, H.Shi, H.Liang. Endothelial cell-derived fibronectin extra domain A promotes colorectal cancer metastasis via inducing epithelial-mesenchymal transition. Carcinogenesis 2014; 35:1661-70; PMID:24743511; http://dx.doi.org/10.1093/carcin/bgu090
57. Z.Raglow, S.M.Thomas. Tumor matrix protein collagen XIalpha1 in cancer. Cancer Letters 2015; 357:448-53; PMID:25511741; http://dx.doi.org/10.1016/j.canlet.2014.12.011
58. J.Stanisavljevic, J.Loubat-Casanovas, M.Herrera, T.Luque, R.Pena, A.Lluch, J.Albanell, F.Bonilla, A.Rovira, C.Peña, et al. Snail1-expressing fibroblasts in the tumor microenvironment display mechanical properties that support metastasis. Cancer Res 2015; 75:284-95; PMID:25488750; http://dx.doi.org/10.1158/0008-5472.CAN-14-1903
59. A.Lochter, M.J.Bissell. Involvement of extracellular matrix constituents in breast cancer. Seminars Cancer Biol 1995; 6:165-73; http://dx.doi.org/10.1006/scbi.1995.0017
60. D.Radisky, J.Muschler, M.J.Bissell. Order and disorder:the role of extracellular matrix in epithelial cancer. Cancer Invest 2002; 20:139-53; PMID:11852996; http://dx.doi.org/10.1081/CNV-120000374
61. Y.N.Niu, S.J.Xia. Stroma-epithelium crosstalk in prostate cancer. Asian J Androl 2009; 11:28-35; PMID:19098934; http://dx.doi.org/10.1038/aja.2008.39
62. P.P.Provenzano, K.W.Eliceiri, J.M.Campbell, D.R.Inman, J.G.White, P.J.Keely. Collagen reorganization at the tumor-stromal interface facilitates local invasion. BMC Med 2006; 4:38; PMID:17190588; http://dx.doi.org/10.1186/1741-7015-4-38
63. Y.Shintani, M.J.Wheelock, K.R.Johnson. Phosphoinositide-3 kinase-Rac1-c-Jun NH2-terminal kinase signaling mediates collagen I-induced cell scattering and upregulation of N-cadherin expression in mouse mammary epithelial cells. Mol Biol Cell 2006; 17:2963-75; PMID:16624865; http://dx.doi.org/10.1091/mbc.E05-12-1123
64. M.Aumailley The laminin family. Cell Adhesion Migration 2013; 7:48-55; PMID:23263632; http://dx.doi.org/10.4161/cam.22826
65. C.M.Horejs, A.Serio, A.Purvis, A.J.Gormley, S.Bertazzo, A.Poliniewicz, A.J.Wang, P.DiMaggio, E.Hohenester, M.M.Stevens. Biologically-active laminin-111 fragment that modulates the epithelial-to-mesenchymal transition in embryonic stem cells. Proc Natl Acad Sci U S A 2014; 111:5908-13
66. Q.K.Chen, K.Lee, D.C.Radisky, C.M.Nelson. Extracellular matrix proteins regulate epithelial-mesenchymal transition in mammary epithelial cells. Differ Res Biol Diversity 2013; 86:126-32; PMID:23660532; http://dx.doi.org/10.1016/j.diff.2013.03.003
67. E.A.Turley. Hyaluronan and cell locomotion. Cancer Metastasis Rev 1992; 11:21-30; PMID:1380898; http://dx.doi.org/10.1007/BF00047600
68. Y.Takahashi, G.Sawada, J.Kurashige, T.Matsumura, R.Uchi, H.Ueo, M.Ishibashi, Y.Takano, S.Akiyoshi, T.Iwaya, et al. Tumor-derived tenascin-C promotes the epithelial-mesenchymal transition in colorectal cancer cells. Anticancer Res 2013; 33:1927-34; PMID:23645740
69. C.P.El-Haibi, G.W.Bell, J.Zhang, A.Y.Collmann, D.Wood, C.M.Scherber, E.Csizmadia, O.Mariani, C.Zhu, A.Campagne, et al. Critical role for lysyl oxidase in mesenchymal stem cell-driven breast cancer malignancy. Proc Natl Acad Sci U S A 2012; 109:17460-5
70. P.Vaupel. Metabolic microenvironment of tumor cells:a key factor in malignant progression. Exp Oncol 2010; 32:125-7; PMID:21403604
71. W.H.Koppenol, P.L.Bounds, C.V.Dang. Otto Warburg's contributions to current concepts of cancer metabolism. Nat Rev Cancer 2011; 11:325-37; PMID:21508971; http://dx.doi.org/10.1038/nrc3038
72. M.Chen, J.Zhang, N.Li, Z.Qian, M.Zhu, Q.Li, J.Zheng, X.Wang, G.Shi. Promoter hypermethylation mediated downregulation of FBP1 in human hepatocellular carcinoma and colon cancer. PloS One 2011; 6:e25564; PMID:22039417; http://dx.doi.org/10.1371/journal.pone.0025564
73. X.Liu, X.Wang, J.Zhang, E.K.Lam, V.Y.Shin, A.S.Cheng, J.Yu, F.K.Chan, J.J.Sung, H.C.Jin. Warburg effect revisited:an epigenetic link between glycolysis and gastric carcinogenesis. Oncogene 2010; 29:442-50; PMID:19881551; http://dx.doi.org/10.1038/onc.2009.332
74. C.Dong, T.Yuan, Y.Wu, Y.Wang, T.W.Fan, S.Miriyala, Y.Lin, J.Yao, J.Shi, T.Kang, et al. Loss of FBP1 by Snail-mediated repression provides metabolic advantages in basal-like breast cancer. Cancer Cell 2013; 23:316-31; PMID:23453623; http://dx.doi.org/10.1016/j.ccr.2013.01.022
75. M.S.Schieber, N.S.Chandel. ROS links glucose metabolism to breast cancer stem cell and EMT phenotype. Cancer Cell 2013; 23:265-7; PMID:23518342; http://dx.doi.org/10.1016/j.ccr.2013.02.021
76. L.Jiang, L.Xiao, H.Sugiura, X.Huang, A.Ali, O.M.Kuro, R.J.Deberardinis, D.A.Boothman. Metabolic reprogramming during TGFβ1-induced epithelial-to-mesenchymal transition. Oncogene 2015; 34:3908-16
77. F.Guan, K.Handa, S.I.Hakomori. Specific glycosphingolipids mediate epithelial-to-mesenchymal transition of human and mouse epithelial cell lines. Proc Natl Acad Sci USA 2009; 106:7461-6
78. A.R.Todeschini, J.N.Dos Santos, K.Handa, S.I.Hakomori. Ganglioside GM2-tetraspanin CD82 complex inhibits met and its cross-talk with integrins, providing a basis for control of cell motility through glycosynapse. J Biol Chem 2007; 282:8123-33; PMID:17215249; http://dx.doi.org/10.1074/jbc.M611407200
79. J.Chang, J.Erler. Hypoxia-mediated metastasis. Adv Exp Med Biol 2014; 772:55-81; PMID:24272354; http://dx.doi.org/10.1007/978-1-4614-5915-6_3
80. F.R.Balkwill, M.Capasso, T.Hagemann. The tumor microenvironment at a glance. J Cell Sci 2012; 125:5591-6; PMID:23420197; http://dx.doi.org/10.1242/jcs.116392
81. D.Hanahan, J.Folkman. Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis. Cell 1996; 86:353-64; PMID:8756718; http://dx.doi.org/10.1016/S0092-8674(00)80108-7
82. K.Ruan, G.Song, G.Ouyang. Role of hypoxia in the hallmarks of human cancer. J Cell Biochem 2009; 107:1053-62; PMID:19479945; http://dx.doi.org/10.1002/jcb.22214
83. M.Hockel, P.Vaupel. Tumor hypoxia:definitions and current clinical, biologic, and molecular aspects. J Natl Cancer Inst 2001; 93:266-76; PMID:11181773; http://dx.doi.org/10.1093/jnci/93.4.266
84. J.Pouyssegur, F.Dayan, N.M.Mazure. Hypoxia signalling in cancer and approaches to enforce tumour regression. Nature 2006; 441:437-43; PMID:16724055; http://dx.doi.org/10.1038/nature04871
85. M.Hockel, K.Schlenger, B.Aral, M.Mitze, U.Schaffer, P.Vaupel. Association between tumor hypoxia and malignant progression in advanced cancer of the uterine cervix. Cancer Res 1996; 56:4509-15; PMID:8813149
86. P.Vaupel, A.Mayer. Hypoxia in cancer:significance and impact on clinical outcome. Cancer Metastasis Rev 2007; 26:225-39; PMID:17440684; http://dx.doi.org/10.1007/s10555-007-9055-1
87. M.Weinmann, C.Belka, L.Plasswilm. Tumour hypoxia:impact on biology, prognosis and treatment of solid malignant tumours. Onkologie 2004; 27:83-90; PMID:15007254; http://dx.doi.org/10.1159/000075611
88. G.L.Semenza Targeting HIF-1 for cancer therapy. Nat Rev Cancer 2003; 3:721-32; PMID:13130303; http://dx.doi.org/10.1038/nrc1187
89. A.Kannan, A.Krishnan, M.Ali, S.Subramaniam, D.Halagowder, N.D.Sivasithamparam. Caveolin-1 promotes gastric cancer progression by up-regulating epithelial to mesenchymal transition by crosstalk of signalling mechanisms under hypoxic condition. Eur J Cancer 2014; 50:204-15; PMID:24070739; http://dx.doi.org/10.1016/j.ejca.2013.08.016
90. T.Ren, W.Zhang, X.Liu, H.Zhao, J.Zhang, J.Zhang, X.Li, Y.Zhang, X.Bu, M.Shi, et al. Discoidin domain receptor 2 (DDR2) promotes breast cancer cell metastasis and the mechanism implicates epithelial-mesenchymal transition programme under hypoxia. J Pathol 2014; 234:526-37; PMID:25130389; http://dx.doi.org/10.1002/path.4415
91. K.H.Cho, M.J.Choi, K.J.Jeong, J.J.Kim, M.H.Hwang, S.C.Shin, C.G.Park, H.Y.Lee. A ROS/STAT3/HIF-1alpha signaling cascade mediates EGF-induced TWIST1 expression and prostate cancer cell invasion. Prostate 2014; 74:528-36; PMID:24435707; http://dx.doi.org/10.1002/pros.22776
92. T.Ide, Y.Kitajima, A.Miyoshi, T.Ohtsuka, M.Mitsuno, K.Ohtaka, Y.Koga, K.Miyazaki. Tumor-stromal cell interaction under hypoxia increases the invasiveness of pancreatic cancer cells through the hepatocyte growth factor/c-Met pathway. Int J Cancer J Int Du Cancer 2006; 119:2750-9; http://dx.doi.org/10.1002/ijc.22178
93. S.A.Mani, W.Guo, M.J.Liao, E.N.Eaton, A.Ayyanan, A.Y.Zhou, M.Brooks, F.Reinhard, C.C.Zhang, M.Shipitsin, et al. The epithelial-mesenchymal transition generates cells with properties of stem cells. Cell 2008; 133:704-15; PMID:18485877; http://dx.doi.org/10.1016/j.cell.2008.03.027
94. A.P.Morel, M.Lievre, C.Thomas, G.Hinkal, S.Ansieau, A.Puisieux. Generation of breast cancer stem cells through epithelial-mesenchymal transition. PloS one 2008; 3:e2888; PMID:18682804; http://dx.doi.org/10.1371/journal.pone.0002888
95. P.Dalerba, R.W.Cho, M.F.Clarke. Cancer stem cells:models and concepts. Ann Rev Med 2007; 58:267-84; PMID:17002552; http://dx.doi.org/10.1146/annurev.med.58.062105.204854
96. K.Polyak, R.A.Weinberg. Transitions between epithelial and mesenchymal states:acquisition of malignant and stem cell traits. Nature Rev Cancer 2009; 9:265-73; http://dx.doi.org/10.1038/nrc2620
97. Y.F.Chou, H.H.Chen, M.Eijpe, A.Yabuuchi, J.G.Chenoweth, P.Tesar, J.Lu, R.D.McKay, N.Geijsen. The growth factor environment defines distinct pluripotent ground states in novel blastocyst-derived stem cells. Cell 2008; 135:449-61; PMID:18984157; http://dx.doi.org/10.1016/j.cell.2008.08.035
98. L.Vermeulen, E.M.F.De Sousa, M.van der Heijden, K.Cameron, J.H.de Jong, T.Borovski, J.B.Tuynman, M.Todaro, C.Merz, H.Rodermond, et al. Wnt activity defines colon cancer stem cells and is regulated by the microenvironment. Nat Cell Biol 2010; 12:468-76; PMID:20418870; http://dx.doi.org/10.1038/ncb2048
99. M.B.Meads, R.A.Gatenby, W.S.Dalton. Environment-mediated drug resistance:a major contributor to minimal residual disease. Nat Rev Cancer 2009; 9:665-74; PMID:19693095; http://dx.doi.org/10.1038/nrc2714
100. L.A.Hazlehurst, S.A.Enkemann, C.A.Beam, R.F.Argilagos, J.Painter, K.H.Shain, S.Saporta, D.Boulware, L.Moscinski, M.Alsina, et al. Genotypic and phenotypic comparisons of de novo and acquired melphalan resistance in an isogenic multiple myeloma cell line model. Cancer Res 2003; 63:7900-6; PMID:14633719
101. J.S.Damiano, A.E.Cress, L.A.Hazlehurst, A.A.Shtil, W.S.Dalton. Cell adhesion mediated drug resistance (CAM-DR):role of integrins and resistance to apoptosis in human myeloma cell lines. Blood 1999; 93:1658-67; PMID:10029595
102. L.A.Hazlehurst, R.F.Argilagos, W.S.Dalton. Beta1 integrin mediated adhesion increases Bim protein degradation and contributes to drug resistance in leukaemia cells. Br J Haematol 2007; 136:269-75; PMID:17233818; http://dx.doi.org/10.1111/j.1365-2141.2006.06435.x
103. B.Klein, X.G.Zhang, Z.Y.Lu, R.Bataille. Interleukin-6 in human multiple myeloma. Blood 1995; 85:863-72; PMID:7849308
104. Z.Zhong, Z.Wen, J.E.Darnell, Jr. Stat3:a STAT family member activated by tyrosine phosphorylation in response to epidermal growth factor and interleukin-6. Science 1994; 264:95-8; PMID:8140422; http://dx.doi.org/10.1126/science.8140422
105. R.Catlett-Falcone, T.H.Landowski, M.M.Oshiro, J.Turkson, A.Levitzki, R.Savino, G.Ciliberto, L.Moscinski, J.L.Fernández-Luna, G.Nuñez, et al. Constitutive activation of Stat3 signaling confers resistance to apoptosis in human U266 myeloma cells. Immunity 1999; 10:105-15; PMID:10023775; http://dx.doi.org/10.1016/S1074-7613(00)80011-4
106. Z.Zhang, J.C.Lee, L.Lin, V.Olivas, V.Au, T.LaFramboise, M.Abdel-Rahman, X.Wang, A.D.Levine, J.K.Rho, et al. Activation of the AXL kinase causes resistance to EGFR-targeted therapy in lung cancer. Nat Genet 2012; 44:852-60; PMID:22751098; http://dx.doi.org/10.1038/ng.2330
107. A.Cano, M.A.Perez-Moreno, I.Rodrigo, A.Locascio, M.J.Blanco, M.G.del Barrio, F.Portillo, M.A.Nieto. The transcription factor snail controls epithelial-mesenchymal transitions by repressing E-cadherin expression. Nat Cell Biol 2000; 2:76-83; PMID:10655586; http://dx.doi.org/10.1038/35000025
108. S.E.Moody, D.Perez, T.C.Pan, C.J.Sarkisian, C.P.Portocarrero, C.J.Sterner, K.L.Notorfrancesco, R.D.Cardiff, L.A.Chodosh. The transcriptional repressor Snail promotes mammary tumor recurrence. Cancer Cell 2005; 8:197-209; PMID:16169465; http://dx.doi.org/10.1016/j.ccr.2005.07.009
109. J.P.Thiery. Epithelial-mesenchymal transitions in tumour progression. Nat Rev Cancer 2002; 2:442-54; PMID:12189386; http://dx.doi.org/10.1038/nrc822
110. L.F.Zhu, Y.Hu, C.C.Yang, X.H.Xu, T.Y.Ning, Z.L.Wang, J.H.Ye, L.K.Liu. Snail overexpression induces an epithelial to mesenchymal transition and cancer stem cell-like properties in SCC9 cells. Lab Invest J Tech Methods Pathol 2012; 92:744-52; http://dx.doi.org/10.1038/labinvest.2012.8
111. V.Evdokimova, C.Tognon, T.Ng, P.Ruzanov, N.Melnyk, D.Fink, A.Sorokin, L.P.Ovchinnikov, E.Davicioni, T.J.Triche, et al. Translational activation of snail1 and other developmentally regulated transcription factors by YB-1 promotes an epithelial-mesenchymal transition. Cancer Cell 2009; 15:402-15; PMID:19411069; http://dx.doi.org/10.1016/j.ccr.2009.03.017
112. S.Vega, A.V.Morales, O.H.Ocana, F.Valdes, I.Fabregat, M.A.Nieto. Snail blocks the cell cycle and confers resistance to cell death. Genes Dev 2004; 18:1131-43; PMID:15155580; http://dx.doi.org/10.1101/gad.294104
113. D.Gao, N.Joshi, H.Choi, S.Ryu, M.Hahn, R.Catena, H.Sadik, P.Argani, P.Wagner, L.T.Vahdat, et al. Myeloid progenitor cells in the premetastatic lung promote metastases by inducing mesenchymal to epithelial transition. Cancer Res 2012; 72:1384-94; PMID:22282653; http://dx.doi.org/10.1158/0008-5472.CAN-11-2905
114. J.I.Fletcher, M.Haber, M.J.Henderson, M.D.Norris. ABC transporters in cancer:more than just drug efflux pumps. Nat Rev Cancer 2010; 10:147-56; PMID:20075923; http://dx.doi.org/10.1038/nrc2789
115. N.Y.Frank, A.Margaryan, Y.Huang, T.Schatton, A.M.Waaga-Gasser, M.Gasser, M.H.Sayegh, W.Sadee, M.H.Frank. ABCB5-mediated doxorubicin transport and chemoresistance in human malignant melanoma. Cancer Res 2005; 65:4320-33; PMID:15899824; http://dx.doi.org/10.1158/0008-5472.CAN-04-3327
116. N.Walsh, S.Kennedy, A.M.Larkin, D.Tryfonopoulos, A.J.Eustace, T.Mahgoub, C.Conway, I.Oglesby, D.Collins, J.Ballot, et al. Membrane transport proteins in human melanoma:associations with tumour aggressiveness and metastasis. Br J Cancer 2010; 102:1157-62; PMID:20234362; http://dx.doi.org/10.1038/sj.bjc.6605590
117. M.Saxena, M.A.Stephens, H.Pathak, A.Rangarajan. Transcription factors that mediate epithelial-mesenchymal transition lead to multidrug resistance by upregulating ABC transporters. Cell Death Dis 2011; 2:e179; PMID:21734725; http://dx.doi.org/10.1038/cddis.2011.61
118. E.A.Clark, T.R.Golub, E.S.Lander, R.O.Hynes. Genomic analysis of metastasis reveals an essential role for RhoC. Nature 2000; 406:532-5; PMID:10952316; http://dx.doi.org/10.1038/35020106
119. D.X.Nguyen, J.Massague. Genetic determinants of cancer metastasis. Nat Rev Genet 2007; 8:341-52; PMID:17440531; http://dx.doi.org/10.1038/nrg2101
120. S.Rafii, D.Lyden. S100 chemokines mediate bookmarking of premetastatic niches. Nat Cell Biol 2006; 8:1321-3; PMID:17139281; http://dx.doi.org/10.1038/ncb1206-1321
121. J.Wels, R.N.Kaplan, S.Rafii, D.Lyden. Migratory neighbors and distant invaders:tumor-associated niche cells. Genes Dev 2008; 22:559-74; PMID:18316475; http://dx.doi.org/10.1101/gad.1636908